Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas

Author(s)Jason N. Barreto, PharmD, Carolyn Mead-Harvey, MS, Ugur Sener, MD

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Vorasidenib is an IDH inhibitor approved for the treatment of grade 2 IDH-mutant gliomas but remains investigational for higher-grade tumors. We evaluated clinical experience with the agent in the setting of IDH-mutant high-grade glioma.